MARKETS
Analyst Actions

BTIG Suspends Neutral Rating on Theravance Biopharma

Sep 24, 2026 · 05:25 AM ET· updated 1h ago

BTIG suspends Neutral rating on Theravance Biopharma (NASDAQ:TBPH).

Share
Why It Matters

An investment analyst paused their neutral rating on Theravance. When an analyst stops rating a stock, watch for news or changes coming soon.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.